HALOZYME THERAPEUTICS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 1,336,974 | $85,312,311 | 1.23% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 1, 2025 |
| June 30, 2025 | 1,291,977 | $67,208,644 | 0.89% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 30, 2025 |
| Sept. 30, 2025 | 1,225,181 | $89,854,775 | 1.16% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Oct. 28, 2025 |
| Dec. 31, 2025 | 1,223,665 | $82,352,655 | 1.07% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 5, 2026 |
| March 31, 2026 | 1,218,668 | $78,762,513 | 1.08% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | April 28, 2026 |
| June 30, 2026 | 1,392,819 | $109,015,943 | 1.17% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 29, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.